Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000, and the commencement of its preclinical programmes. The round was led by The Rainbow Seed Fund who co-invested alongside Finance Wales and Dr Mark McCamish. Proceeds will be used by the company to validate […]
read moreBritish molecular diagnostics company Cytox plans to make a molecular test for the early-stage diagnosis of Alzheimer’s disease available in the US by year end. The Oxford-based firm is also in discussions with multiple pharmaceutical and biotechnology companies that wish to use its test, which is run on a custom Affymetrix microarray, to select patients […]
read more— Early-stage venture fund key in bridging gap between UK research and commercialisation — Fund aims to turn UK scientific ‘world’s first’ ambitions into market-leading companies Rainbow Seed Fund, an early-stage venture capital fund focused on promising technologies developed at the UK’s largest publicly-funded research facilities and campuses, today announces that the fund have now […]
read more